A Dividend Cut Just Created A 9.2% Monthly Dividend Bargain

BlackRock Health Sciences Term Trust (BMEZ) recently enacted a dividend cut, which, despite triggering an initial market sell-off, is framed as a strategic 'reset' to a sustainable 9.2% yield. The fund currently trades at an 11% discount to its net asset value, with BlackRock engaging in share repurchases, signaling potential value. The article highlights that BMEZ's portfolio, heavily weighted in biotech and medical device innovators, is favorably positioned to benefit from a potentially less regulated healthcare environment, particularly under a future Trump administration, echoing their strong performance during the Trump 1.0 era.

Analysis

BlackRock Health Sciences Term Trust (BMEZ) recently enacted a dividend adjustment, which triggered a market sell-off and expanded its discount to net asset value (NAV) to 11%. Despite this, the fund now offers a 9.2% yield, a level management has positioned as a sustainable reset to a consistent 11 cents per month. This strategic pivot is reinforced by a share repurchase program from BlackRock, signaling confidence in the fund's underlying value. BMEZ's portfolio is heavily weighted toward biotech and medical device innovators, with top holdings including Alnylam (ALNY), Veeva Systems (VEEV), and Dexcom (DXCM). The investment thesis is predicated on the potential for these types of companies to thrive under a lighter regulatory regime, citing their past performance during the Trump 1.0 administration where they delivered gains of over 300%. The current 11% discount to NAV therefore presents an opportunity to acquire these assets for 89 cents on the dollar, a valuation that may already incorporate the market's reaction to the dividend news.

Key Decisions for Investors

• Investors may consider the 11% discount to NAV and the reset 9.2% yield as a compelling entry point, particularly given the confidence signal from BlackRock's own share repurchase program.
• The investment case leans heavily on a specific political and regulatory outlook for the healthcare sector, so investors should monitor political developments and their potential impact on M&A activity and regulation.
• It is crucial to track the performance of the fund's key underlying holdings, such as Alnylam (ALNY) and Veeva Systems (VEEV), as their fundamentals are the primary long-term driver of the fund's NAV.
• Monitor the fund's discount to NAV, as a narrowing of this gap could provide significant capital appreciation in addition to the high dividend yield.